• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
?
-

Resources for You

Tracleer (bosentan) 62.5 and 125 mg Tablets February 2009

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View

 

Sections Modified

Summary of Changes to Contraindications and Warnings

WARNINGS

  • Decreased Sperm Counts

ADVERSE REACTIONS

  • Post-Marketing Experience

WARNINGS

  • Decreased Sperm Counts
    • An open-label, single arm, multicenter, safety study evaluated the effect on testicular function of TRACLEER.....Based on these findings and preclinical data from endothelin receptor antagonists, it cannot be excluded that endothelin receptor antagonists such as TRACLEER have an adverse effect on spermatogenesis

MEDICATION GUIDE

  • What are the possible side effects of Tracleer
    • Sperm Count Reduction
      • Reduced sperm counts have been observed ....